المؤلفون: Miyamoto, Kenichi, Takashima, Atsuo, Mizusawa, Junki, Sato, Yuya, Shimada, Yasuhiro, Katayama, Hiroshi, Nakamura, Kenichi, Shibata, Taro, Fukuda, Haruhiko, Shida, Dai, Kanemitsu, Yukihide, Hamaguchi, Tetsuya

المساهمون: National Cancer Center Research and Development Fund, Japan Agency for Medical Research and Development

المصدر: Japanese Journal of Clinical Oncology ; volume 49, issue 10, page 985-990 ; ISSN 1465-3621

الوصف: Adjuvant chemotherapy is the current standard treatment for stage III colorectal cancer after curative resection. However, the prognosis of stage III colorectal cancer is still poor even after curative resection and adjuvant chemotherapy. Several observational studies suggested that the anti-tumor effect of aspirin. Therefore, we planned a randomized double-blind placebo-controlled phase III trial, which commenced in Japan in March 2018, to confirm the superiority of aspirin over placebo added to adjuvant chemotherapy in terms of disease-free survival (DFS) for stage III colorectal cancer patients after curative resection. A total of 880 patients will be accrued from 20 Japanese institutions within 3 years. The primary endpoint is DFS and the secondary endpoints are overall survival, relapse-free survival, relative dose intensity, adverse events, and serious adverse events. This trial has been registered at Japan Registry of Clinical Trials as jRCTs031180009 (https://jrct.niph.go.jp/detail/589Test).

الإتاحة: https://doi.org/10.1093/jjco/hyz106Test
http://academic.oup.com/jjco/article-pdf/49/10/985/33032854/hyz106.pdfTest

المؤلفون: Kadota, Tomohiro, Saito, Ryuta, Kumabe, Toshihiro, Mizusawa, Junki, Katayama, Hiroshi, Sumi, Minako, Igaki, Hiroshi, Kinoshita, Manabu, Komori, Takashi, Ichimura, Koichi, Narita, Yoshitaka, Nishikawa, Ryo

المساهمون: Japan Agency for Medical Research and Development, National Cancer Center Research and Development Fund

المصدر: Japanese Journal of Clinical Oncology ; volume 49, issue 12, page 1172-1175 ; ISSN 1465-3621

مصطلحات موضوعية: Cancer Research, Radiology, Nuclear Medicine and imaging, Oncology, General Medicine

الوصف: A randomized phase III trial in Japan commenced in June 2019. The present standard treatment for newly diagnosed glioblastoma is maximal resection followed by chemoradiotherapy with temozolomide. The purpose of this study is to confirm the superiority of maximal resection with carmustine wafer implantation followed by chemoradiotherapy with temozolomide over the standard maximal resection followed by chemoradiotherapy with temozolomide in terms of overall survival for newly diagnosed glioblastoma. A total of 250 patients will be accrued from 35 Japanese institutions in 5.5 years. Patients with >90% surgical resection will be registered and randomly assigned to each group with 1:1 allocation. The primary endpoint is overall survival and the secondary endpoints are progression-free survival, loco-regional progression-free survival and incidence of adverse events. This trial has been registered in the Japan Registry of Clinical Trial, as jRCT1031190035 [https://jrct.niph.go.jp/en-latest-detail/jRCT1031190035Test].

الإتاحة: https://doi.org/10.1093/jjco/hyz169Test
http://academic.oup.com/jjco/article-pdf/49/12/1172/31639205/hyz169.pdfTest

المؤلفون: Moritani, Konosuke, Kanemitsu, Yukihide, Shida, Dai, Shitara, Kohei, Mizusawa, Junki, Katayama, Hiroshi, Hamaguchi, Tetsuya, Shimada, Yasuhiro

المساهمون: National Cancer Center Research and Development

المصدر: Japanese Journal of Clinical Oncology ; volume 50, issue 1, page 89-93 ; ISSN 1465-3621

مصطلحات موضوعية: Cancer Research, Radiology, Nuclear Medicine and imaging, Oncology, General Medicine

الوصف: It is controversial whether chemotherapy with or without primary tumour resection is effective for the patients with incurable Stage IV colorectal cancer. A randomized controlled trial, initiated in Japan in 2012, is being conducted to evaluate the survival benefit and safety of primary tumour resection plus chemotherapy compared with chemotherapy alone in asymptomatic Stage IV colorectal cancer patients with unresectable metastatic disease. Patients are randomly assigned to either chemotherapy alone or primary tumour resection followed by chemotherapy. The primary endpoint is overall survival. Secondary endpoints are progression-free survival, incidence of adverse events, proportion of patients with R0 resection and proportion of palliative surgery for the chemotherapy-alone group. This trial was registered in June 2012 with the UMIN Clinical Trials Registry as UMIN000008147 [http://www.umin.ac.jp/ctr/index-j.htmTest]. In December 2017, the study protocol was amended for reducing sample size. A total of 280 patients will be enrolled over the course of 8.5 years.

الإتاحة: https://doi.org/10.1093/jjco/hyz173Test
http://academic.oup.com/jjco/article-pdf/50/1/89/31952777/hyz173.pdfTest

المؤلفون: Jia, Ning, Tong, Hanxing, Zhang, Yong, Katayama, Hiroshi, Wang, Yuan, Lu, Weiqi, Zhang, Sumei, Wang, Jin

المساهمون: National Natural Science Foundation of China

المصدر: Frontiers in Genetics ; volume 10 ; ISSN 1664-8021

مصطلحات موضوعية: Genetics (clinical), Genetics, Molecular Medicine

الإتاحة: https://doi.org/10.3389/fgene.2019.00825Test

المؤلفون: Katayama, Hiroshi, Murata, Koichi, Lee, Deok-joo

المصدر: Procedia Manufacturing ; volume 39, page 599-608 ; ISSN 2351-9789

مصطلحات موضوعية: Artificial Intelligence, Industrial and Manufacturing Engineering

الإتاحة: https://doi.org/10.1016/j.promfg.2020.01.427Test
https://api.elsevier.com/content/article/PII:S2351978920304996?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2351978920304996?httpAccept=text/plainTest

المؤلفون: Chen, Youyi, Sumardika, I Wayan, Tomonobu, Nahoko, Winarsa Ruma, I Made, Kinoshita, Rie, Kondo, Eisaku, Inoue, Yusuke, Sato, Hiroki, Yamauchi, Akira, Murata, Hitoshi, Yamamoto, Ken-ichi, Tomida, Shuta, Shien, Kazuhiko, Yamamoto, Hiromasa, Soh, Junichi, Liu, Ming, Futami, Junichiro, Sasai, Kaori, Katayama, Hiroshi, Kubo, Miyoko, Putranto, Endy Widya, Hibino, Toshihiko, Sun, Bei, Nishibori, Masahiro, Toyooka, Shinichi, Sakaguchi, Masakiyo

المساهمون: P-CREATE, Japan Agency for Medical Research and Development, JSPS KAKENHI, Takeda Science Foundation, Princess Takamatsu Cancer Research Fund, Kobayashi Foundation for Cancer Research, Japanese Foundation For Cancer Research, Fujii Memorial Medical Science Foundation

المصدر: Cancer Letters ; volume 452, page 178-190 ; ISSN 0304-3835

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.canlet.2019.03.023Test
https://api.elsevier.com/content/article/PII:S030438351930179X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S030438351930179X?httpAccept=text/plainTest

المؤلفون: Katayama, Hiroshi

المصدر: Experimental Dermatology ; volume 27, issue 10, page 1084-1091 ; ISSN 0906-6705 1600-0625

الوصف: Remarkable effects of anti‐ IL ‐17A and anti‐ IL ‐23 antibodies on psoriasis indicate deep involvement of IL ‐23/Th17 axis in the pathogenesis of psoriasis. According to the current immune theory, activation of dendritic cells initiates the generation of this axis. However, this theory is not enough to explain the mechanism, because the process of this activation is obscure and the antigen that is recognized by antigen‐presenting cells and pathogenic T cells has long been unidentified. Therefore, I thought of another theory as follows. Neutrophils are attracted by LTB 4 at subcorneal portion and infiltrate into the epidermis. At the time of neutrophil migration through the basement membrane, basal keratinocytes in G0/G1 phase enter the cell cycle and begin to proliferate, according to the principle, “detachment‐mediated cell proliferation.” This passing is continuously repeated and leads to elongation of rete ridges. The IL ‐23/Th17 axis is generated by interactions between infiltrated neutrophils and keratinocytes. Briefly, neutrophils infiltrated into the epidermis secrete IL ‐17A, which acts on keratinocytes to express CCL 20, a ligand for the chemokine receptor CCR 6. Keratinocytes perturbed by neutrophil infiltration produce HSP 70, followed by production of IL ‐23 via TLR 4 using HSP 70 as an endogenous ligand for TLR 4. Natural Th17 cells expressing CCR 6 are recruited to psoriatic epidermis and expand there in the presence of IL ‐23 and IL ‐1β. In this manner, the framework of the IL ‐23/Th17 axis is created, which acts to maintain or exacerbate psoriasis. Noteworthy is the fact that this axis causes positive feedback loop, starting from IL ‐17A production by neutrophils and ending in IL ‐17A production by nT h17 cells. Therapeutic mechanisms of anti‐ IL ‐17A and anti‐ IL ‐23 antibodies, targeting neutrophils, were also described.

الإتاحة: https://doi.org/10.1111/exd.13746Test

المؤلفون: Ezoe, Yasumasa, Mizusawa, Junki, Katayama, Hiroshi, Kataoka, Kozo, Muto, Manabu

المساهمون: 武藤, 学, 40360698

مصطلحات موضوعية: hyponatremia, platinum agent, cisplatin, carboplatin, risk factors

الوصف: Background: Hyponatremia is a common electrolyte abnormality in cancer patients who receive chemotherapy. Among anticancer agents, platinum-based agents are reported to cause chemotherapy-induced hyponatremia. However, the actual incidence and risk factors remain unknown. Results: The reports of 29 trials were analyzed. The incidence of grade 3/4 hyponatremia was 11.9% in patients treated with platinum-based chemotherapy and 3.8% in those treated with nonplatinum-based regimens (P < 0.01). Univariable analysis revealed a high incidence of hyponatremia in patients receiving cisplatin, three-drug combination regimen, two-drug combination regimen with amrubicin or irinotecan, or high-dose cisplatin (weekly equivalent cisplatin dose ≥20 mg/m²), and in patients with small-cell lung cancer. Conclusion: This is the first report of the actual incidence and the potential risk factors of chemotherapy-induced hyponatremia. Careful monitoring of serum sodium level is needed when platinum-based chemotherapy is administered. Methods: This study included all clinical trials of systemic chemotherapies for solid cancers that were conducted by the Japan Clinical Oncology Group (JCOG) after January 2000 and of which the patient enrolment was completed by January 2014. The latest reports of each trial were used for analysis. The incidence of chemotherapy-induced grade 3/4 hyponatremia and the potential risk factors were investigated with univariable analysis.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/2433/255285Test; Oncotarget; 6595; 6606

الإتاحة: http://hdl.handle.net/2433/255285Test

المؤلفون: Wakabayashi, Toshihiko, Natsume, Atsushi, Mizusawa, Junki, Katayama, Hiroshi, Fukuda, Haruhiko, Sumi, Minako, Nishikawa, Ryo, Narita, Yoshitaka, Muragaki, Yoshihiro, Maruyama, Takashi, Ito, Tamio, Beppu, Takaaki, Nakamura, Hideo, Kayama, Takamasa, Sato, Shinya, Nagane, Motoo, Mishima, Kazuhiko, Nakasu, Yoko, Kurisu, Kaoru, Yamasaki, Fumiyuki, Sugiyama, Kazuhiko, Onishi, Takanori, Iwadate, Yasuo, Terasaki, Mizuhiko, Kobayashi, Hiroyuki, Matsumura, Akira, Ishikawa, Eiichi, Sasaki, Hikaru, Mukasa, Akitake, Matsuo, Takayuki, Hirano, Hirofumi, Kumabe, Toshihiro, Shinoura, Nobusada, Hashimoto, Naoya, Aoki, Tomokazu, Asai, Akio, Abe, Tatsuya, Yoshino, Atsuo, Arakawa, Yoshiki, Asano, Kenichiro, Yoshimoto, Koji, Shibui, Soichiro, Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)

المساهمون: 荒川, 芳輝, 20378649

مصطلحات موضوعية: Glioblastoma, Interferon-beta, Temozolomide, MGMT, RCT

الوصف: Purpose: This study explored the superiority of temozolomide (TMZ) + interferonβ (IFNβ) to standard TMZ as treatment for newly diagnosed glioblastoma (GBM) via randomized phase II screening design. ; Experimental design: Eligibility criteria included histologically proven GBM, with 50% of the tumor located in supratentorial areas, without involvement of the optic, olfactory nerves, and pituitary gland and without multiple lesions and dissemination. Patients in the TMZ + radiotherapy (RT) arm received RT (2.0 Gy/fr/day, 30 fr) with TMZ (75 mg/m², daily) followed by TMZ maintenance (100–200 mg/m²/day, days 1–5, every 4 weeks) for 2 years. Patients in the TMZ + IFNβ + RT arm intravenously received IFNβ (3 MU/body, alternative days during RT and day 1, every 4 weeks during maintenance period) and TMZ + RT. The primary endpoint was overall survival (OS). The planned sample size was 120 (one-sided alpha 0.2; power 0.8). ; Results: Between Apr 2010 and Jan 2012, 122 patients were randomized. The median OS with TMZ + RT and TMZ + IFNβ + RT was 20.3 and 24.0 months (HR 1.00, 95% CI 0.65–1.55; one-sided log rank P = 0.51). The median progression-free survival times were 10.1 and 8.5 months (HR 1.25, 95% CI 0.85–1.84). The incidence of neutropenia with the TMZ + RT and the TMZ + IFNβ + RT (grade 3–4, CTCAE version 3.0) was 12.7 versus 20.7% during concomitant period and was 3.6 versus 9.3% during maintenance period. The incidence of lymphopenia was 54.0 versus 63.8% and 34.5 versus 41.9%. ; Conclusions: TMZ + IFNβ + RT is not considered as a candidate for the following phase III trial, and TMZ + RT remained to be a most promising treatment. This trial was registered with the UMIN Clinical Trials Registry: UMIN000003466.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/2433/232946Test; Journal of neuro-oncology; 138; 627; 636

الإتاحة: http://hdl.handle.net/2433/232946Test

المؤلفون: Ochi, Nobuaki, Wakabayashi, Tokio, Urakami, Atsushi, Yamatsuji, Tomoki, Ikemoto, Naoto, Nagasaki, Yasunari, Nakagawa, Nozomu, Honda, Yoshihiro, Nakanishi, Hidekazu, Yamane, Hiromichi, Monobe, Yasumasa, Akisada, Takeshi, Katayama, Hiroshi, Naomoto, Yoshio, Takigawa, Nagio

المصدر: Therapeutics and Clinical Risk Management ; volume Volume 14, page 2013-2017 ; ISSN 1178-203X

الإتاحة: https://doi.org/10.2147/tcrm.s176520Test
https://www.dovepress.com/getfile.php?fileID=45412Test